Wall Street Is Tripling Its Micron Targets, Not Just Raising Them

Targets That Tripled, Not Inched Higher

The tell isn't that analysts raised their Micron targets — it's the size of the moves. Needham's N. Quinn Bolton took his target from $500 to $1,550, roughly a 3x revision, citing a strong pricing environment, limited capacity additions, and multi-year demand visibility rather than a normal up-cycle. TD Cowen went from $660 to $1,500. Bank of America reset to $1,500 on the same thesis.

These aren't 10% bumps you'd see after a good quarter. A target that triples is an analyst admitting the old framework was wrong — that memory was being modeled as a cyclical commodity when it has started behaving like a capacity-constrained AI input. With the sell side now sitting at 38 buys against a single sell, the debate has shifted from *if* memory re-rates to *how high the multiple goes*.

The $100 Billion Order Book

What lets analysts underwrite those numbers is contracted demand. Alongside the print, Micron disclosed 16 strategic customer agreements representing roughly $100 billion in minimum contracted revenue, with HBM capacity effectively sold out. Memory has historically traded at a discount precisely because nobody could see two quarters ahead; a backlog of this size removes a chunk of that demand-uncertainty discount.

The quarter itself gave them the margin to believe it. Revenue of $41.46 billion was up 346% year over year at a company-record 84.9% gross margin, with non-GAAP EPS of $25.11. The forward guide is what actually moved targets: Micron projected Q4 revenue of $50 billion, about $7 billion above consensus, with gross margin near 86% and EPS of roughly $31. When the next quarter is guided higher than this one, the cyclical-peak narrative gets very hard to argue.

Where the Perp Sits

On Hyperliquid, MU is up 24.33% over 16 hours to about $1,245, clearing the $1,213.56 all-time high set on June 22 ahead of the report. Part of that move predates the earnings — the stock ran hard into the print — so this is continuation, not a clean reaction candle. The HIP-3 market has turned over roughly $665 million in 24h volume.

The thing to weigh from here: at ~$1,245 the stock is already within striking distance of the brand-new $1,500 targets, meaning much of the 'validation' is priced in rather than ahead of it. The bull case is now consensus, and the risk is the same one that's haunted memory forever — pricing and capacity discipline. The $100 billion backlog softens that, but any crack in HBM pricing or a wave of competing capacity is what would invalidate the re-rate, not a soft quarter.